home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Amino

SHARESHARESHARE
Amino is a healthcare financial wellness benefit that eliminates barriers for employees and their families to access affordable, high-quality medical care. Combining data, design, and consumer-first thinking, Amino offers guidance features that curate each users personalized matches for in-network facilities and provides concierge appointment booking with nearly every doctor in America. Paired with a modern HSA, Amino’s mission is to deliver smarter savings at every turn, so companies and employees get the most from their health insurance plans.
SHARESHARESHARE

RELATED NEWS


Oxford Drug Design has received over 8 million pounds in grant and equity investment from CARB-X, the UK Department of Health and Social Care (DHSC) and o2h Ventures. The funding will help to develop new antibiotics effective against drug-resistant superbugs, and to expand Oxford Drug Design’s proprietary machine learning computational platform - the Dual-Target aminoacyl-tRNA Synthetase inhibitor (DaaRSi) project. The research is important as drug-resistant superbugs are on the rise world...

READ MORE

Teva has expanded a recall of losartan potassium tablets after tests revealed a potential human carcinogen in the blood pressure drug. The Israeli pharma earlier this week recalled six lots of the drug containing unacceptable levels of a nitrosamine impurity. This builds on a decision in April when Teva withdrew 35 lots after detecting the same impurity known as NMBA (N-Nitroso-N-methyl-4-aminobutyric acid). According to a recall notice shared by the FDA, Teva had sold bulk lots of the drug to C...

READ MORE

A small biotech, MacroGenics, took the market by surprise earlier this year with some surprising data from its margetuximab essentially a tweaked version of Roche’s Herceptin (trastuzumab) where a few amino acid mutations are enough to produce a stronger cellular response to cancer.CEO Scott Koenig has been doing the rounds at the American Society of Clinical Oncology (ASCO) conference in Chicago following release of detailed data from the SOPHIA trial of margetuximab in breast cancer pati...

READ MORE

A new treatment hailed as ‘groundbreaking’ has been rolled out across the country as part of the NHS' Long Term Plan, and could see as many as 2,000 patients benefit as a result. 5-ALA (5-AminoLevulinic Acid), dubbed ‘the pink drink’, uses fluorescent dye and ultraviolet light to make cancerous cells glow under UV light, enabling surgeons to more accurately identify the affected areas of the brain. This method will help to tackle some of the hardest to treat cases and...

READ MORE

British scientists in a breakthrough study, have found a natural replacement for chemotherapy in lung cancer patients, as they have demonstrated how tiny particles derived from tea leaves can restrain the growth of lung cancer cells, destroying up to 80 percent of them. The researchers from Swansea University’s College of Engineering in the United Kingdom, found that these tiny particles, called “quantum dots,” are 400 times thinner than a human hair, and producing them from te...

READ MORE

Hi-Tech Pharmaceuticals once again states that FDA's attempt to quasi ban a product by warning letter rather than rulemaking is not the law. Hi-Tech is working on a response to the agency but wanted consumers to know Hi-Tech will not just roll over due to an ill informed warning letter. Hi-Tech Pharmaceuticals was forced to sue the FDA November 5th, 2013 in Federal Court because the agency bypassed standard rule-making procedures in favor of a bullying campaign to try to force companies to d...
HI-TECH PHARMACEUTICALS, INC.
READ MORE

As recalls on blood pressure drugs continue to plague drugmakers, the FDA declared a slate of 40 generic pills safe to use. On Thursday, the agency released a list of 40 generic angiotensin II receptor blockers (ARBs) that are free of three potentially carcinogenic compounds linked to various “sartan” drugs, including valsartan and losartan. The FDA launched a global recall in 2018 after a U.S. drug manufacturer found high levels of N-nitrosodimethylamine (NDMA) in the valsartan acti...
FIERCEPHARMA
READ MORE

Despite releasing positive data on its Phase III ENVISION trial, Alnylam Pharmaceuticals stock dropped 7.5 percent. Although not completely clear why the drop may be related to a high percentage of serious adverse events observed in the trial. The ENVISION Phase III trial evaluated givosiran, an investigational RNAi therapeutic that targets aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP). AHP is a family of rare, genetic diseases characterized by possibl...

READ MORE

More carcinogens have been discovered in blood pressure medications, which has prompted another recall by the U.S. Food and Drug Administration (FDA). On Friday, the FDA raised concerns about losartan potassium tablets sold by India-based Hetero Labs Ltd. and distributed by Camber Pharmaceuticals. The FDA said the medication used to treat high blood pressure and heart failure contained an impurity called N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), a known carcinogen. The FDA said this is the ...

READ MORE

For millions of people across the globe, cholesterol has become a significant health issue. It also turns out that cholesterol can be a problem for some cancer cells. New research coming from Rockefeller University reveals that a rare tumor type is unable to synthesize cholesterol, which is something that cells need to survive. The discovery was made after researchers began to look at ways to cut off tumors from the nutrients needed to survive and thrive. Kivanc Bisroy, the Chapman Perelman Assi...

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...